Article info
PDFClinical and epidemiological research
Extended report
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
- Correspondence to Dr Mark Genovese, Division of Immunology and Rheumatology, Stanford University, 1000 Welch Rd #203, Palo Alto, CA 94304, USA; Genovese{at}Stanford.edu
Citation
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
Publication history
- Received October 3, 2012
- Revised November 21, 2012
- Accepted November 27, 2012
- First published December 25, 2012.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions